Treatment concerns for bullous pemphigoid in theCOVID-19 pandemic era

Bullous pemphigoid (BP) is the most common autoimmune blistering disease with subepidermal involvement, typically affecting the elderly. It has spontaneous remissions and exacerbations with significant morbidity. A novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the new universal coronavirus disease 2019 (COVID-19) pandemic. The pandemic made concerns, especially about immunosuppressive therapy. In this article, we reviewed the management of BP in the COVID-19 pandemic era. The data about the best management of autoimmune bullous diseases like BP, during the outbreak of COVID-19, are evolving and updated every day.